Terns Pharmaceuticals announced the appointment of Melita Sun Jung as chief business officer, effective April 22. Jung joins Terns with more than 20 years of experience in the life sciences industry, leading corporate strategy and business development, commercial planning and execution, financings and investment management. Most recently, she served as chief business officer at Structure Therapeutics.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TERN:
- Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
- 3 Best Stocks to Buy Now, 4/4/2024, According to Top Analysts
- Terns Pharmaceuticals price target lowered to $18 from $19 at UBS
- Terns Pharmaceuticals price target lowered to $15 from $17 at JMP Securities
- Terns Pharmaceuticals reports Q4 EPS (29c), consensus (29c)
